The effects of abaloparatide on hip geometry and biomechanical properties in Japanese osteoporotic patients assessed using DXA-based hip structural analysis: results of the Japanese phase 3 ACTIVE-J trial

What Was Tested

The paper reports a study of Abaloparatide, published as a randomized controlled trial.

To evaluate the effect of ABL on hip geometry and biomechanical properties, hip structural analysis (HSA) was performed using ACTIVE-J trial data.

Who Took Part

PubMed tags the participants as both men and women.

Hip dual-energy X-ray absorptiometry scans from postmenopausal women and men (ABL, n = 128; placebo, n = 65) at baseline and up to week 78 were analyzed to extract bone geometric parameters at the narrow neck (NN), intertrochanteric region (IT), and proximal femoral shaft (FS).

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Because people in this Abaloparatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The comparison arm used a placebo, so changes seen with Abaloparatide could be set against what happens without it.

Computed tomography (CT)-based BMD and HSA indices were compared between baseline and week 78.

What Was Measured

The subject headings attached to it are Absorptiometry, Photon, Bone Density, East Asian People, Femur Neck, Fractures, Bone, Osteoporosis and Parathyroid Hormone-Related Protein.

Author keywords: Abaloparatide, Bone mineral density, Dual-energy X-ray absorptiometry, Hip geometry and Hip structural analysis.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Abaloparatide.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (Archives of osteoporosis), a journal based in England.

More context: the Abaloparatide compound page, all human trials.